First Header Logo Second Header Logo

Araya Puwanant MD

TitleAssociate Professor
InstitutionWake Forest School of Medicine
DepartmentNeurology
Address
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of Pittsburgh, Pittsburgh, PAMS2021Clinical Reserach
    Prince of Songkla University , ThailandMD1998Doctor of Medicine
    Collapse awards and honors
    2011 - 2013MDA Clinical Research Training Award, University of Rochester
    2016NINDS Clinical Trial Methodology Course , NINDS

    Collapse Research 
    Collapse research activities and funding
    MDA480577     (Araya Puwanant)Feb 1, 2017 - Jan 30, 2023
    Muscular Dystrophy Association (MDA)
    Regional Body Composition and Clinical Endpoints in Myotonic Dystrophy
    Role Description: The major goal of this longitudinal study is to identify sensitive endpoints for progressive muscle weakness and atrophy in myotonic dystrophy.
    Role: PI
    NCTIC Pilot Grant     (Bushnell/Milligan)Dec 1, 2019 - Dec 31, 2020
    Wake Forest Neuroscience Clinical Trials and Innovation Center (NCTIC)
    Brain Structure and Cognitive Endpoints in Myotonic Dystrophy Type 2 (BRACE-MD2)
    Role Description: The focus of this program is to help foster junior investigators to develop new translational research projects with the strategic focus area of neuroscience that will lead to extramural funding support
    Role: Pilot Grant Awardee
    1R61NS117210     (Thurman Wheeler)Jun 15, 2021 - May 31, 2025
    NIH/NINDS
    Extracellular RNA biomarkers of myotonic dystrophy type 1
    Role Description: Myotonic dystrophy is an inherited disorder that causes progressive muscle weakness and wasting. There is no cure. The purpose of this proposal is to develop novel strategies that will accelerate the discovery of effective treatments using biofluid and non-invasive approach.
    Role: Co-Investigator
    ADRC Development Project Grant     (Araya Puwanant)Jul 1, 2022 - Jun 30, 2024
    Wake Forest ADRC
    Characterizing Tau Mis-processing in Myotonic Dystrophy
    Role Description: This project aims to characterize tau profiling and evaluate in vitro tau-PET and novel microtubule-targeted radiotracers in post-mortem brain tissues of patients with myotonic dystrophy type 2, and establish proof-of-concept that tau misprocessing is associated with brain pathology.
    Role: PI of the Project
    1K23NS125110     (Araya Puwanant)Jul 1, 2022 - Jun 30, 2027
    NIH/NINDS
    Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2
    Role Description: The overall goals of this K23 application are to evaluate the relationship between brain structure and function on cognition and motor performance in patients with DM2, and thereby contribute to PI’s preparation to independently lead future research elucidating the neurobiology of DM2.
    Role: PI

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Narayanaswami P, Sanders DB, Thomas L, Thibault D, Blevins J, Desai R, Krueger A, Bibeau K, Liu B, Guptill JT. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study. Lancet Neurol. 2024 Mar; 23(3):267-276. PMID: 38365379.
      Citations:    
    2. Ebert SE, Meiling JB, Caress JB, Gandhi Mehta RK, Baute Penry V, Puwanant A, Cartwright MS. Clinical Utility and Diagnostic Yield of Genetic Testing for Inherited Neuromuscular Disorders in a Single, Large Neuromuscular Center. Neurol Clin Pract. 2024 Apr; 14(2):e200268. PMID: 38585444.
      Citations:    
    3. Madrid DA, Knapp RA, Lynch D, Clemens P, Weaver AA, Puwanant A. Associations between lower extremity muscle fat fraction and motor performance in myotonic dystrophy type 2: A pilot study. Muscle Nerve. 2023 Mar 20. PMID: 36938823.
      Citations:    
    4. Graves TD, Griggs RC, Bundy BN, Jen JC, Baloh RW, Hanna MG. Episodic Ataxia Type 1: Natural History and Effect on Quality of Life. Cerebellum. 2023 Aug; 22(4):578-586. PMID: 35655106.
      Citations:    
    5. Heatwole C, Luebbe E, Rosero S, Eichinger K, Martens W, Hilbert J, Dekdebrun J, Dilek N, Zizzi C, Johnson N, Puwanant A, Tawil R, Schifitto G, Beck CA, Richeson JF, Zareba W, Thornton C, McDermott MP, Moxley R. Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial. Neurology. 2021 01 12; 96(2):e228-e240. PMID: 33046619.
      Citations:    
    6. Puwanant A, Isfort M, Lacomis D, Živkovic SA. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul Disord. 2019 02; 29(2):127-133. PMID: 30638612.
      Citations:    
    7. Lacomis D, Puwanant A. What is in the Neuromuscular Junction Literature? J Clin Neuromuscul Dis. 2018 Dec; 20(2):76-84. PMID: 30439753.
      Citations:    
    8. Simmons DB, Lanning J, Cleland JC, Puwanant A, Twydell PT, Griggs RC, Tawil R, Logigian EL. Long Exercise Test in Periodic Paralysis: A Bayesian Analysis. Muscle Nerve. 2019 01; 59(1):47-54. PMID: 29752813.
      Citations:    
    9. Gonzalez NL, Puwanant A, Lu A, Marks SM, Živkovic SA. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review. Neuromuscul Disord. 2017 Mar; 27(3):266-268. PMID: 28109638.
      Citations:    
    10. Harada Y, Puwanant A, Herrmann DN. Hereditary Neuropathy With Liability to Pressure Palsies: Diverse Phenotypes in Childhood. J Clin Neuromuscul Dis. 2016 Dec; 18(2):79-83. PMID: 27861220.
      Citations:    
    11. Heatwole C, Bode R, Johnson NE, Dekdebrun J, Dilek N, Eichinger K, Hilbert JE, Logigian E, Luebbe E, Martens W, Mcdermott MP, Pandya S, Puwanant A, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT. Myotonic dystrophy health index: Correlations with clinical tests and patient function. Muscle Nerve. 2016 Feb; 53(2):183-90. PMID: 26044513.
      Citations:    
    12. Graves TD, Cha YH, Hahn AF, Barohn R, Salajegheh MK, Griggs RC, Bundy BN, Jen JC, Baloh RW, Hanna MG. Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation. Brain. 2014 Apr; 137(Pt 4):1009-18. PMID: 24578548.
      Citations:    
    13. Nakamori M, Sobczak K, Puwanant A, Welle S, Eichinger K, Pandya S, Dekdebrun J, Heatwole CR, McDermott MP, Chen T, Cline M, Tawil R, Osborne RJ, Wheeler TM, Swanson MS, Moxley RT, Thornton CA. Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol. 2013 Dec; 74(6):862-72. PMID: 23929620.
      Citations:    
    14. Puwanant A, Herrmann DN. Multifocal acquired demyelinating sensory and motor neuropathy. Neurology. 2012 Oct 16; 79(16):1742. PMID: 23071167.
      Citations:    
    15. Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, Salajegheh MK, Venance SL, Ciafaloni E, Matthews E, Meola G, Herbelin L, Griggs RC, Barohn RJ, Hanna MG. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA. 2012 Oct 03; 308(13):1357-65. PMID: 23032552.
      Citations:    
    16. Murphy SM, Puwanant A, Griggs RC. Unintended effects of orphan product designation for rare neurological diseases. Ann Neurol. 2012 Oct; 72(4):481-90. PMID: 23109143.
      Citations:    
    17. Puwanant A, Evangelisti SM, Griggs RC. Treating the chief complaint: hand rejuvenation for Hirayama disease. Neurology. 2011 Jul 12; 77(2):190-1. PMID: 21715710.
      Citations:    
    18. Puwanant A, Ruff RL. INa and IKir are reduced in Type 1 hypokalemic and thyrotoxic periodic paralysis. Muscle Nerve. 2010 Sep; 42(3):315-27. PMID: 20589886.
      Citations:    
    19. Imerman KW, Miles JD, Park I, Puwanant A, Daroff RB, Qureshi S. Highlights from International Meetings: American Academy of Neurology AAN 61st Annual Meeting, Seattle, April 25th - May 2, 2009. Neurosciences (Riyadh). 2009 Jul; 14(3):310-3. PMID: 21048644.
      Citations:    
    20. Koubeissi MZ, Puwanant A, Jehi L, Alshekhlee A. In-hospital complications of epilepsy surgery: a six-year nationwide experience. Br J Neurosurg. 2009; 23(5):524-9. PMID: 19718552.
      Citations:    
    21. Kusner LL, Puwanant A, Kaminski HJ. Ocular myasthenia: diagnosis, treatment, and pathogenesis. Neurologist. 2006 Sep; 12(5):231-9. PMID: 16990734.
      Citations:    
    22. Chotinaiwattarakul W, Puwanant A, Poungvarin N, Senanarong V. . Catatonia in an HIV-infected Patient: A Case Report and Review of the Literature. Neurology J Thai . 2004; 1(1):15-19.
    23. Puwanant A, Arayawichanont A, Charnnarong N, Nidhinandana S, Komoltri C, Poungvarin N. The Prognostic Assessment of Thai Intracerebral Hemorrhage: PATCH score. Intern Med J Thai. 2004; 20(1):296-303.
    Puwanant's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (120)
    Explore
    _
    Co-Authors (1)
    Explore
    _
    Similar People (51)
    Explore
    _
    Same Department Expand Description
    Explore
    _